cnbc_topnews

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out and the return drops to just 2.9%, down from 3.8% in 2024.

obesity drugs now account for 38% of projected commercial inflows from the late-stage pipeline, and 25% of total forecast sales — up from 1% in 2022. for the first time in 16 years, oncology has been overtaken as the biggest contributor to late-stage pipeline value. deloitte's hanno ronte told cnbc: "it is a bubble, because so much is concentrated."

concentration is extreme: just 54 mega-blockbuster indications — 9% of the late-stage cohort — are forecast to generate 70% of total risk-adjusted peak sales. ronte said the bubble won't burst for patients, but the market has become overly dependent on a handful of assets, leaving the sector exposed to therapeutic-area-specific shocks.

source: cnbc_topnews
sentiment: -0.50 · impact: 0.60

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

AI chipmaker Cerebras targets $3.5 billion raise in IPO

ai chipmaker cerebras filed for an ipo on the nasdaq, aiming to raise up to $3.5 billion. it plans to sell 28 million shares at $115 to $125 each, which could value the company at $26.6 billion. that's up from a $23 billion valuation in a

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

AI chipmaker Cerebras targets $3.5 billion raise in IPO